Sunovion submits NDA for dasotraline in ADHD

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) submitted an NDA to FDA for dasotraline (SEP-225289) to treat ADHD. The dopamine and norepinephrine reup...